Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
The DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Abstract
Maintaining research and development (R&D) productivity at a sustainable level is one of the main challenges currently facing the pharmaceutical industry. In this article, we discuss the results of a comprehensive longitudinal review of AstraZeneca's small-molecule drug projects from 2005 to 2010. The analysis allowed us to establish a framework based on the five most important technical determinants of project success and pipeline quality, which we describe as the five 'R's: the right target, the right patient, the right tissue, the right safety and the right commercial potential. A sixth factor - the right culture - is also crucial in encouraging effective decision-making based on these technical determinants. AstraZeneca is currently applying this framework to guide its R&D teams, and although it is too early to demonstrate whether this has improved the company's R&D productivity, we present our data and analysis here in the hope that it may assist the industry overall in addressing this key challenge.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is accumulating evidence that the success of candidate drugs is greatly enhanced if the drug target is independently confirmed by human genetic data.16, 17”
From Early Neurological Change After Ischemic Stroke Is Associated With 90-Day Outcome (2021) · cites this paper as [16]
In the citing paper
“Currently, techniques like structural magnetic resonance imaging (MRI), and molecular imaging of deposited Aβ and tau proteins using positron emission tomography (PET), are highly accurate in detecting the presence of pathophysiological and neuropathological changes of AD and are used in the drug development [10, 11].”
From Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease (2020) · cites this paper as [10]
In the citing paper
“In the past, other medical fields tried to address similar problems by increasing the volume of trials.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [106]
In the citing paper
“In reality, research and development costs increased while the number of drugs approved remained static106,107.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [106]
In the citing paper
“Early initiation of PK/PD assessment facilitates understanding of the biology by validating and confirming target engagement.50”
From Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development (2018) · cites this paper as [50]
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 4×
“Although clinical validation was not confirmed in the Phase IIa studies, retrospective analysis suggested that AZD1981 showed limited efficacy in an atopic/allergic asthma population selected by a positive skin prick test.”
BackgroundInfluentialInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Genomic responses in mouse models poorly mimic human inflammatory diseases
Seok, J., Warren, H. S., Cuenca, A. G., Mindrinos, M. N., Baker, H. V., Xu, W., Richards, D. R., McDonald-Smith, G. P., Gao, H., Hennessy, L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222878110 · Cited by 3,005 · cited 1×
“29 (13) Dose limited by compound characteristics or tissue exposure not established”
BackgroundPavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981 · cited 1×
“11 (5) Evidence from previous phase not robust enough”
BackgroundLeckie, M. J., Brinke, A. T., Khan, J., Diamant, Z., O'Connor, B. J., Walls, C. M., Mathur, A. K., Cowley, H. C., Chung, K. F., Djukanovic, R., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03496-6 · Cited by 1,814
Lebrikizumab Treatment in Adults with Asthma
Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat, P. E., Parsey, M. V., Arron, J. R., Harris, J. M., Scheerens, H., Wu, L. C., Su, Z., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106469 · Cited by 1,514
Research works printed but not linked: 3
- Herper, M. The truly staggering cost of inventing new drugs. Forbes [online] , (10 Feb 2012).
- Redfern, W. et al. Impact and frequency of different toxicities throughout the pharmaceutical life cycle. The Toxicologist 114, 231 (2010).
- Quirk, M. et al. Abstract P-09-045. Effects of low-trapping NMDA channel blocker AZD6765 on gamma-band EEG and psychotomimetic liability: a comparison to ketamine in freely behaving rats. Int. J. Neuropsychopharmacol. 15 (Suppl. S1), 153 (2012).
Cited by
Items 701–800 of 1,000
Ramya, S., Loganathan, T., Chandran, M., Priyanka, R., Kavipriya, K., Pushpalatha, G. G. L., Devaraj, A., Abraham, G., & Jayakumararaj, R. (2022) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v12i2-s.5286 · Cited by 11
A cross-disease, pleiotropy-driven approach for therapeutic target prioritization and evaluation
Bao, C., Tan, T., Wang, S., Gao, C., Lu, C., Yang, S., Diao, Y., Jiang, L., Jing, D., Chen, L., et al. (2024) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100757 · Cited by 13
“8 This shift is motivated by retrospective analyses revealing that human genetic evidence supporting drug-target pairs significantly enhances the success rate of drug development, 9–11 especially when drugs are supported by targets with a causal relation to the disease.”
Contractility assessment using aligned human iPSC-derived cardiomyocytes
Satsuka, A., Ribeiro, A. J. S., Kawagishi, H., Yanagida, S., Hirata, N., Yoshinaga, T., Kurokawa, J., Sugiyama, A., Strauss, D. G., & Kanda, Y. (2024) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2024.107530 · Cited by 11
Baldassarro, V. A., Dolci, L. S., Mangano, C., Giardino, L., Gualandi, C., Focarete, M. L., & Calzà, L. (2016) · BioResearch open access · doi:10.1089/biores.2016.0025 · Cited by 11
“The right cell-culture has actually been recognized as one of the six most important technical determinants of project success and pipeline quality by the pharmaceutical industry.(10) We then tested the effect of PLLA scaffold on viability and differentiation using three cell systems widely used in the field, that is,…”
MethodBujar, M., Donelan, R., McAuslane, N., Walker, S., & Salek, S. (2016) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479016662681 · Cited by 11
Visser, S. A. G., & Bueters, T. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.08.006 · Cited by 12
Teng, M., Wu, W., Li, Z., Yang, G., Qin, J., Wang, Y., Hu, Z., Dong, H., Hou, L., Hu, G., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.10.010 · Cited by 12
Foulkes, M. J., Tolliday, F. H., Henry, K. M., Renshaw, S. A., & Jones, S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240231 · Cited by 12
Determinants of radical drug innovation: a systematic literature review
Stiller, I., van Witteloostuijn, A. C., & Cambré, B. (2021) · Management Review Quarterly · doi:10.1007/s11301-021-00218-9 · Cited by 17
Safavi, M., Sabourian, R., & Abdollahi, M. R. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1217196 · Cited by 12
Fragment Prioritization on a Large Mutagenicity Dataset
Floris, M., Raitano, G., Medda, R., & Benfenati, E. (2016) · Molecular Informatics · doi:10.1002/minf.201600133 · Cited by 11
Boussommier-Calleja, A. (2020) · Bioengineering Innovative Solutions for Cancer · doi:10.1016/b978-0-12-813886-1.00013-9 · Cited by 10
Innovations in skin microphysiological systems for nonclinical testing and FDA modernization
Lee, T., Kyung, S. Y., Kwon, M., Park, B., & Ko, J. (2026) · Microsystems & Nanoengineering · doi:10.1038/s41378-025-01149-1 · Cited by 18
Heishima, K., Aketa, N., Heishima, M., & Kawachi, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1250766 · Cited by 13
Vellaiyan, V., Allaka, T. R., Bhoomandla, S., Vudari, B., Chepuri, K., & Nagarajaiah, H. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.141189 · Cited by 10
Translational PK/PD: a retrospective analysis of performance and impact from a drug portfolio
Jansson‐Löfmark, R., Fridén, M., Badolo, L., Ahlström, C., Gurrell, I. K., Pangalos, M. N., & Jones, R. D. O. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104417 · Cited by 10
Self-citationStem cells in cardiovascular diseases: turning bad days into good ones.
de Oliveira, M. E. B. S., Saldanha-Araújo, F., de Goes, A. M., Costa, F. F., & de Carvalho, J. D. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.07.012 · Cited by 9
Ligand-receptor binding kinetics in drug design
Borisov, D. V., & Veselovsky, A. V. (2020) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20206601042 · Cited by 12
Nájera, G. S., Narganes-Carlón, D., & Crowther, D. J. (2021) · Scientific Reports · doi:10.1038/s41598-021-94897-9 · Cited by 13
Arora, A., Nain, P., Kumari, R., & Kaur, J. (2021) · Archives of Pharmacy Practice · doi:10.51847/yjqdk2wtgx · Cited by 12
“An additional factor to this framework is the right culture, i.e. where the data and facts are not manipulated and confronted honestly [63].”
BackgroundFang, H. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac379 · Cited by 10
Narganes-Carlón, D., Crowther, D. J., & Pearson, E. R. (2023) · Scientific Reports · doi:10.1038/s41598-023-35597-4 · Cited by 16
Ishibashi, Y., Nagafuku, N., Kinoshita, K., Okamura, A., Shirakawa, T., & Suzuki, I. (2023) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2023.116675 · Cited by 10
Accelerating drug development at Bristol Myers Squibb through innovation
Viraswami-Appanna, K., Buenconsejo, J., Baidoo, C. A., Chan, I. S. F., Li, D., Balan, M. M., Tiwari, R. C., Yang, L., & Sethuraman, V. S. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.103952 · Cited by 10
Sternebring, O., Alifrangis, L. H., Christensen, T. F., Ji, H., Hegelund, A. C., & Högerkorp, C. (2015) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21277 · Cited by 11
“one of the key elements in this new approach (38).”
BackgroundPredicting clinically promising therapeutic hypotheses using tensor factorization
Yao, J. J., Hurle, M. R., Nelson, M. R., & Agarwal, P. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2664-1 · Cited by 13
“, modulating the target’s activity did not provide a statistically significant benefit to patients [1, 2].”
BackgroundFactors affecting the choice for plant-based products in drug discoveries
Anywar, G., & Namukobe, J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817890-4.00002-0 · Cited by 10
Further Considerations Towards an Effective and Efficient Oncology Drug Discovery DMPK Strategy
Williamson, B., Colclough, N., Fretland, A. J., Jones, B., Jones, R. D. O., & McGinnity, D. F. (2020) · Current Drug Metabolism · doi:10.2174/1389200221666200312104837 · Cited by 10
Murphy, B. A., Tadin‐Strapps, M., Jensen, K., Mogg, R., Liaw, A. I., Herath, K. B., Bhat, G., McLaren, D. G., Previs, S. F., & Pinto, S. (2017) · Metabolism · doi:10.1016/j.metabol.2017.02.015 · Cited by 11
Virtual Screening and Lead Discovery
Singh, N. K., Maiti, N. J., Mishra, M., Raj, S., Rakshit, G., Ghosh, R., & Roy, S. (2024) · Wiley eBooks · doi:10.1002/9781394249190.ch5 · Cited by 11
Activity in Group-Housed Home Cages of Mice as a Novel Preclinical Biomarker in Oncology Studies
Terry, S., Gommet, C., Kerangueven, A.-C., Leguet, M., Thévenin, V., Berthelot, M., Begoud, L., Windenberger, F., & Lainée, P. (2023) · Cancers · doi:10.3390/cancers15194798 · Cited by 11
“…successful clinical studies, there is a need for continued improvement of in vitro, in situ, and in vivo preclinical models and their monitoring, while recognizing that animal studies remain a standard for establishing evidence of the link between a pharmacological target and human disease [7–10].”
Target identification and validation in research
Keerthana, N., & Koteeswaran, K. (2024) · World Journal of Biology Pharmacy and Health Sciences · doi:10.30574/wjbphs.2024.17.3.0116 · Cited by 12
“Patients with a better understanding of their genetic risks and treatment options can make informed choices (25).”
BackgroundChen, H., Lu, D. X., Xiao, Z., Li, S., Zhang, W., Luan, X., Zhang, W., & Zheng, G. (2024) · Health Information Science and Systems · doi:10.1007/s13755-024-00300-y · Cited by 11
“It has been reported that about 20% preclinical studies are terminated by safety concerns of drug targets and 48% failures of clinical trials are associated with drug targets [14].”
Yamazaki, D., & Ishida, S. (2024) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2024.101047 · Cited by 11
Applications of pharmacometrics in drug development
Xiong, Y., Samtani, M. N., & Ouellet, D. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115503 · Cited by 10
Quantitative and qualitative concordance between clinical and nonclinical toxicity data
Weitekamp, C. A., Friedman, K. P., Harrill, A. H., Auerbach, S., Bandele, O. J., Barton‐Maclaren, T. S., Fitzpatrick, S., Mezencev, R., Santillo, M. F., Simanainen, U., et al. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfaf071 · Cited by 11
Nanomaterials targeting cancer stem cells to overcome drug resistance and tumor recurrence
Kumbhakar, D. V., Thakkar, L., Akhand, C., Sharaf, S., & Vemuganti, G. K. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1499283 · Cited by 14
Current status and future prospects of toxicity assessment using organoids
Nguyen, X., & Yoo, J. (2025) · Toxicological Research · doi:10.1007/s43188-025-00298-9 · Cited by 13
“CNS adverse effects were estimated to account for 7% and 34% of drug development project discontinuations in the preclinical and clinical trial stages, respectively [20].”
Gangwal, A., & Lavecchia, A. (2026) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.70072 · Cited by 13
Supporting Innovation in Early-Stage Pharmaceutical Development Decisions
Methling, F., Borden, S. A., Veeraraghavan, D., Sommer, I., Siebert, J. U., von Nitzsch, R., & Seidler, M. (2022) · Decision Analysis · doi:10.1287/deca.2022.0452 · Cited by 10
Utility of human cytochrome P450 inhibition data in the assessment of drug-induced liver injury
Kaito, S., Takeshita, J., Iwata, M., Sasaki, T., Hosaka, T., Shizu, R., & Yoshinari, K. (2024) · Xenobiotica · doi:10.1080/00498254.2024.2312505 · Cited by 8
“In particular, drug-induced liver injury (DILI) is a major cause of the withdrawal of approved drugs from the market and the discontinuation of drug candidate development (Frank and Hargreaves 2003; Wilke et al. 2007; Cook et al. 2014).”
Biomarkers for Precision Patient Selection in Cancer Therapy Approvals in the US, from 2011 to 2023
Dou, Y. N., Grimstein, C., Mascaro, J., & Wang, J. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3306 · Cited by 12
“33 The evolving nature of FDA’s decisions on approving indications in all-comers vs. biomarker-defined populations reflects a nuanced consideration of various factors, driven by biological rationale and clinical evidence.”
Layton, M. E., Reif, A. J., Hartingh, T. J., Rodzinak, K. J., Dudkin, V., Wang, C., Arrington, K. L., Kelly, M. J., Garbaccio, R. M., O’Brien, J. A., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.01.021 · Cited by 9
ADME Optimization in Drug Discovery
McGinnity, D. F., & Grime, K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12365-0 · Cited by 10
Opportunities and challenges of implementing Pharmacogenomics in cancer drug development
Tarantino, P., Trapani, D., Morganti, S., Ferraro, E., Viale, G., D’Amico, P., Duso, B. A., & Curigliano, G. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2018.22 · Cited by 11
“A paper published in 2014 by AstraZeneca’s scientists analyzed nearly 150 drug development projects at the company, to identify cornerstones of trial failure([12]); “five Rs” where found to be the most important technical determinants of project success and pipeline quality: the right target, the right patient, the ri…”
BackgroundZheng, Q. S., Wang, R., Zhang, N., Wang, C., & Li, P. (2020) · Xenobiotica · doi:10.1080/00498254.2020.1765265 · Cited by 9
Osum, S. H., Coutts, A. W., Duerre, D. J., Tschida, B. R., Kirstein, M. N., Fisher, J. E., Bell, W. R., Delpuech, O., Smith, P. D., Widemann, B. C., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab020 · Cited by 14
Fu, Y., Taghvafard, H., Said, M. M., Rossman, E. I., Collins, T. A., Billiald‐Desquand, S., Leishman, D. J., van der Graaf, P. H., van Hasselt, J. G. C., & Snelder, N. (2022) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12774 · Cited by 9
“In the MOA- identification analyses, the site of action of new compounds could be identified correctly with three combinations of observations: (1) HR, CO, dP/dtmax, and MAP; (2) HR, dP/dtmax, and MAP; and (3) HR and MAP.”
MethodLiachenko, S., Ramu, J., Paule, M., & Hanig, J. (2018) · Neurotoxicology · doi:10.1016/j.neuro.2018.02.004 · Cited by 4
“The safety of newly developed drug candidates is the most important reason for the high rates of attrition during preclinical development, which contributes greatly to the increased cost and long time required to bring new medications to the market (Cook et al., 2014).”
BackgroundTranslational Scoring of Candidate Treatments for Alzheimer’s Disease: A Systematic Approach
Cummings, J. L. (2020) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000507569 · Cited by 10
Izzedine, H. (2018) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2017.06.006 · Cited by 9
The value of companion diagnostics in oncology drug development
Conn, C., & Jin, J. Y. (2022) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2100697 · Cited by 9
“It has been demonstrated that biomarker-directed drug development programs are associated with a higher level of success compared to drug development programs that are not biomarker directed [1,2].”
BackgroundPatel, A., Poddar, S., Nierenberg, D., Lang, S., Wang, H., de Mello, C. P. P., Gamarra, J., Colón, A., Kennedy, P., Roles, J., et al. (2024) · Current Research in Toxicology · doi:10.1016/j.crtox.2024.100209 · Cited by 9
Klein, J. A., Heidmann, J. D., Kiyota, T., Fullerton, A. M., Homan, K. A., & Co, J. Y. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1508820 · Cited by 10
Elsaman, T., Mohamed, M. A., Elderdery, A. Y., Alsrhani, A., Alzahrani, B., Ghanem, H. B., Mills, J. J., Rayzah, M., Alzerwi, N. A. N., Alsultan, A. A., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1531512 · Cited by 8
DILI prediction in drug development: present and future
Uetrecht, J. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2495955 · Cited by 13
“Although there are several new theories for methods to predict iDILI risk, there does not appear to have been a significant decrease in the fraction of drugs that are withdrawn because of iDILI in phase II clinical trials and beyond since the turn of the century [40].”
Loh, J. S., Low, C. Y., Low, W. P., Ng, Y. L., Mak, W. Q., Tan, L., Chan, H. H., Ong, Y. S., Cheah, S. K. A., Albert, E. L., et al. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01923-8 · Cited by 9
“In fact, this framework contributed to a fourfold increase in the overall project success rate between 2012 and 2016 compared to 2005 and 2010 [18, 19 ].”
Aleo, M. D., Doshna, C. M., Baltrukonis, D. J., Fortner, J. H., Drupa, C. A., Navetta, K. A., Fritz, C. A., Potter, D. M., Verdugo, M. E., & Beierschmitt, W. P. (2019) · Journal of Applied Toxicology · doi:10.1002/jat.3822 · Cited by 11
“Safety findings in nonclinical toxicology studies can account for ~40% of pharmaceutical drug attrition (Waring et al., 2015), while some individual companies report up to twice that amount (Cook et al., 2014).”
BackgroundPharmacokinetic Properties of Moracin C in Mice
You, B. H., BasavanaGowda, M. K., Lee, J. U., Chin, Y., Choi, W. J., & Choi, Y. H. (2021) · Planta Medica · doi:10.1055/a-1321-1519 · Cited by 9
Wallman, M., Borghardt, J. M., Martel, E., Pairet, N., Markert, M., & Jirstrand, M. (2022) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2022.107171 · Cited by 8
Drennan, P. G., Karponis, D., Richards, D. B., Coles, M. C., & Fullerton, J. N. (2022) · Clinical and Translational Science · doi:10.1111/cts.13457 · Cited by 9
Why Therapeutic Trials Fail in Primary Tauopathies
Olfati, N., Ghodsi, H., Bayram, E., & Litvan, I. (2023) · Movement Disorders · doi:10.1002/mds.29322 · Cited by 8
Sanz, M., Carrillo de Albornoz, A., Martín, C., Needleman, I., & Tonetti, M. S. (2023) · Journal of Clinical Periodontology · doi:10.1111/jcpe.13805 · Cited by 8
“This result is in line with other publications highlighting the interest from the industry in developing good-quality products for a highly productive environment (Cook et al., 2014; Shimura et al., 2014a, 2014b).”
ResultApplication of machine learning to predict unbound drug bioavailability in the brain
Morales, J. F., Ruiz, M. E., Stratford, R. E., & Talevi, A. (2024) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2024.1360732 · Cited by 8
Pawluk, E., Delaunois, A. G., Gamboa, B., & Valentin, J. (2024) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2024.107537 · Cited by 8
Huber, K. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2295 · Cited by 10
Improving machine learning in early drug discovery
Bendtsen, C., Degasperi, A., Ahlberg, E., & Carlsson, L. (2017) · Annals of Mathematics and Artificial Intelligence · doi:10.1007/s10472-017-9541-2 · Cited by 10
“For these reasons much effort is being invested within the pharmaceutical industry on improving the R&D process [5].”
BackgroundMaynard, J., Emmas, S.-A., Blé, F.-X., Barjat, H., Lawrie, E., Hancox, U. J., Polanska, U. M., Pritchard, A., & Hudson, K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183048 · Cited by 8
Heart Rate Variability as a Translational Biomarker for Emotional and Cognitive Deficits
Ellenbroek, B. A., Kidwell, M., Colussi‐Mas, J., & Youn, J. (2019) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-803161-2.00013-8 · Cited by 9
Translational imaging in toxicology
Liachenko, S. M. (2020) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2020.03.006 · Cited by 8
A compound attributes-based predictive model for drug induced liver injury in humans
Liu, Y., Gao, H., & He, Y. D. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231252 · Cited by 9
“High-profile drug attrition substantially hinders R&D productivity, with unacceptable safety often a reason for failures [2].”
BackgroundObal, D., & Wu, J. C. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15228 · Cited by 8
“In addition, these drugs are suspected to be associated with congenital heart disease and brain defects as well as autism spectrum disorders (Brambrink et al., 2010; Davidson et al., 2016).”
BackgroundA functional long‐term 2D serum‐free human hepatic in vitro system for drug evaluation
Oleaga, C., Bridges, L. R., Persaud, K., McAleer, C. W., Long, C. J., & Hickman, J. J. (2020) · Biotechnology Progress · doi:10.1002/btpr.3069 · Cited by 8
“As stated by the FDA,(1) thorough studies are required during the preclinical phase in in vitro and in vivo models to predict human toxicity; toward this end, better research tools are needed.(2) Novel in vitro systems that enable cellular function measurements for long-term drug”
BackgroundApplications de l’intelligence artificielle au développement de nouveaux médicaments
Moingeon, P. E. (2021) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2021.01.008 · Cited by 12
Modeling schizophrenia with iPS cell technology and disease mouse models
Nakazawa, T. (2021) · Neuroscience Research · doi:10.1016/j.neures.2021.08.002 · Cited by 9
Leveraging modeling and simulation to optimize the therapeutic window for epigenetic modifier drugs
Walz, A., Vyver, A. J. V. D., Li, Y., Birtwistle, M. R., Krogan, N. J., & Bouhaddou, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108162 · Cited by 8
Talevi, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00108-0 · Cited by 11
Saleh, M. A. A., Bloemberg, J. S., Elassaiss‐Schaap, J., & de Lange, E. C. M. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03281-3 · Cited by 8
“Unestablished target site PK has resulted in as high as one-third of the failures observed in drug development in general (116).”
BackgroundMany are called, few are chosen: the role of science in drug development decisions
Colen, L., Belderbos, R., Kelchtermans, S., & Leten, B. (2023) · The Journal of Technology Transfer · doi:10.1007/s10961-022-09982-6 · Cited by 9
“…a fit between disease, target and drug, but also for designing effective clinical trials that have to establish the best drug candidates for a specific disease (Kola & Landis, 2004; Waring et al., 2015; Barrenho, Miraldo, and Smith 2013; Cook et al., 2014; Chiou et al., 2016; Hay et al., 2014).”
Genetic Rat Models for Schizophrenia
Ellenbroek, B. A., & Karl, T. (2015) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-800981-9.00018-3 · Cited by 10
Industrial medicinal chemistry insights: neuroscience hit generation at Janssen
Tresadern, G., Rombouts, F. J. R., Oehlrich, D., Macdonald, G. J., & Trabanco, A. A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.05.013 · Cited by 9
Translational Safety Biomarkers of Kidney Injury
Troth, S. P., Vlasáková, K., Amur, S., Amin, R. P., & Glaab, W. E. (2019) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.12.008 · Cited by 8
Current Clinical Trials for Tinnitus
Dyhrfjeld‐Johnsen, J., & Cederroth, C. R. (2020) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2020.03.012 · Cited by 8
Disease Models: Lung Models for Testing Drugs Against Inflammation and Infection
Carius, P., Horstmann, J. C., Carvalho‐Wodarz, C. D. S., & Lehr, C. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_366 · Cited by 8
Taleuzzaman, M., Jahangir, M. A., Chauhan, S., Kala, C., & Beg, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821095-6.00007-0 · Cited by 8
Diogo, D., Tian, C., Franklin, C. S., Alanne-Kinnunen, M., March, M., Spencer, C. C. A., Vangjeli, C., Weale, M. E., Mattsson, H., Kilpeläinen, E., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/218875 · Cited by 8
A Framework for Managing InnovationPreprint
Kavadias, S., & Hutchison‐Krupat, J. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3615824 · Cited by 15
Kenna, J. G. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1290082 · Cited by 7
“Project failures due to animal toxicities or human ADRs are leading reasons why drug discovery and development is a highly inefficient and very costly process [5,6,9,10].”
BackgroundDebad, S. J., Allen, D., Bandele, O. J., Bishop, C. E., Blaylock, M., Brown, P., Bunger, M. K., Co, J. Y., Crosby, L. M., Daniel, A. B., et al. (2024) · ALTEX · doi:10.14573/altex.2403261 · Cited by 11
“In some instances, GIT toxicity in clinical trials or during marketing is not adequately balanced by the benefit, and use of the drug may be suspended (Qureshi et al., 2011; Cook et al., 2014).”
BackgroundGuo, Y., He, Y., Zhu, Y., Zhang, W., Lin, H., Zhao, M., Zhang, J., Bai, Y., Wei, Z., Xia, Y., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103919 · Cited by 8
Remez, N., García-Serna, R., Vidal, D., & Mestres, J. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00470 · Cited by 9
Target Engagement Measures in Preclinical Drug Discovery: Theory, Methods, and Case Studies
Durham, T. B., & Wiley, M. R. (2017) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-50042-3_3 · Cited by 7
Gaudriault, P., Fassini, D., & Homs-Corbera, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-817202-5.00008-5 · Cited by 7
Kim, S., You, B. H., Bae, M., Han, S. Y., Jung, K., & Choi, Y. H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092277 · Cited by 7
Chengan, K., Hind, C. K., Stanley, M., Wand, M. E., Nagappa, L. K., Howland, K., Hanson, T., Martín‐Escolano, R., Tsaousis, A. D., Bengoechea, J. A., et al. (2023) · npj Antimicrobials and Resistance · doi:10.1038/s44259-023-00018-z · Cited by 9
“While a similar approach can be performed with in vitro approaches (e.g., puri fi ed ribosomes, enzyme complexes and mutants), target inhibition of an isolated protein has so far failed to deliver new antibiotic candidates to the clinic, despite extensive high-throughput screening studies 59 .”
Vlasveld, M., Callegaro, G., Fisher, C., Eakins, J. A., Walker, P., Lok, S., van Oost, S., de Jong, B., Pellegrino-Coppola, D., Burger, G. A., et al. (2024) · Liver International · doi:10.1111/liv.15822 · Cited by 9
“4 We anticipate that mechanism-based testing using human-relevant test methods will be pivotal to advance the assessment of DILI risk for novel drug candidates.”
MethodPan, Z., Seto, W., Liu, C., Mao, Y., Alqahtani, S. A., & Eslam, M. (2024) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-23-562 · Cited by 11
Rao, J., Wang, T., Wang, K., & Qiu, F. (2024) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2024.116992 · Cited by 9
Adverse Outcome Pathway and Machine Learning to Predict Drug Induced Seizure Liability
Lane, T. R., Snyder, S. H., Harris, J. S., Urbina, F., & Ekins, S. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00177 · Cited by 7
Barbaric, I., Allison, T. F., Powles-Glover, N. S., Biga, V., & Andrews, P. W. (2015) · International Journal of High Throughput Screening · doi:10.2147/ijhts.s58113 · Cited by 9
“This review also highlights the importance of having a solid understanding of the drug target biology and the disease indication for a successful outcome of a drug project.(4) As previously indicated, in vitro models are widely utilized in preclinical development, and these are often humanized models.”
Metadata
- Authors
- Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Pangalos, Menelas N.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-05-16
- Volume
- 13
- Issue
- 6
- Pages
- 419-431
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1967105697
- Cited by
- 1,344
- References
- 75
- Citations by year
- 2026: 90 · 2025: 92 · 2024: 104 · 2023: 110 · 2022: 99 · 2021: 123 · 2020: 118 · 2019: 125 · 2018: 131 · 2017: 115 · 2016: 124 · 2015: 92 · 2014: 20
- FWCI
- 33.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- AstraZeneca, drug development pipeline, small molecule drug development, R&D productivity, project success factors, target selection, patient selection, tissue selection, drug safety, business potential, organizational culture, pharmaceutical industry
- MeSH terms
- Animals, Clinical Trials as Topic, Decision Making, Organizational, Drug Industry, Drug Evaluation, Preclinical, Humans, Research Support as Topic, Technology, Pharmaceutical, Drug Design, Organizational Culture, Drugs, Investigational, Models, Organizational, Efficiency, Organizational, Biomedical Research, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.